• Neuroderm Ltd., of Ness Ziona, Israel, said results from a Phase I study in volunteers and preliminary data from a Phase IIa study in advanced Parkinson's patients showed that ND0612 was found to be safe and tolerable and maintained steady state, clinically meaningful levodopa plasma concentrations.
